PFIC is a rare and life-threatening liver disease with no approved pharmacologic treatment option. A4250 is an ileal bile acid transporter (IBAT) inhibitor, which is being developed for
The approval has been given for treatment of patients whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. Merck said that the
An independent data monitoring committee (IDMC) has recommended the partnership to stop the trials of lanabecestat, as it is unlikely to meet primary endpoints. AstraZeneca IMED biotech unit
The two companies have entered into a multi-year research and development collaboration to develop the vaccines for a maximum of five undisclosed infectious disease pathogens. As per the
Tagrisso is a third-generation and irreversible EGFR-TKI designed to suppress both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases. The approval was based on data
The approval for the drug regimen is for CLL and SLL patients, with or without 17p deletion, and who had received more than one prior therapy. Venclexta is
Considered to be potentially life-threatening, pemphigus vulgaris is an autoimmune blistering disease that affects the skin and mucous membranes. Patients with this condition suffer from progressive painful blistering
Through using LentiVector platform, Oxford BioMedica has developed OXB-102 gene therapy for Parkinson’s disease. OXB-102, now renamed AXO-Lenti-PD, is a lentiviral gene therapy with a clinically validated mechanism
The US pharma giant will allocate nearly a quarter of this investment, about $150m on neuroscience. The company will also invest on other therapeutic areas of interest like
The Swiss drugmaker had submitted a supplemental biologics license application to the US regulator, covering the data recorded from the phase 3 Haven 3 study. Hemlibra’s priority review
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.